SUBSCRIBE TO OUR RSS
INITIAL PUBLIC OFFERINGS
An Open Window
Life Sciences companies that have gone public since August 2009.
The Burrill Report
April 08, 2010
[Please login to post comments]
Proposed EU Data Protection Rules Could Impede Cancer Research
Position paper argues that wording of regulation has unintended consequences.
Five Life Sciences Companies Price IPOs below Target Midpoint
Enthusiasm wanes as the newly public biotechs trade flat or down out the gate.
Gilead Sciences on a Roll
Biotech reports huge Q2 earnings jump, gains FDA approval and EU nod for new cancer drug.
Drugmakers Share Shelved Compounds with UK Researchers
MRC researchers will study them to help understand the biology of disease, and possibly to repurpose them.
Breaking through the Sequencing Bottleneck
Podcast: July 28, 2014
Sage Therapeutics Scores $90M in Upsized IPO
Strong demand raises confidence for more such deals.
AbbVie and Shire Agree to $54B Union
Chicago-based AbbVie will move headquarters to U.K. in biggest tax inversion deal to date.
FDA Approves Ruconest to Treat Rare Genetic Disease
Salix and Pharming’s new biologic is produced in the milk of transgenic rabbits.
The Changing Patent Landscape for Genome 2.0
Podcast: July 21, 2014
Genetic Risk for Autism Mostly from Common Gene Variants
Study estimates roles of heritability, mutations, and environment as causing the disorder.
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER